Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01028209 · ClinicalTrials.gov registry record · Phase 1
Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
A Phase 1 study, sponsored by Institute for Neurodegenerative Disorders.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01028209 is a Phase 1 study that was terminated before completion, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 12 participants.
The verdict
NCT01028209, a Phase 1 study, was terminated before completion, sponsored by Institute for Neurodegenerative Disorders.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The underlying goal of this study is to assess \[18F\] PBR06 PET imaging as a tool to detect microglial activation in the brain of Alzheimer Disease (AD), Parkinson Disease (PD) and Multiple Sclerosis (MS) research participants.
Interventions
- DRUG [18F] PBR06
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-09-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01028209
The ClinicalTrials.gov registry entry for NCT01028209 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institute for Neurodegenerative Disorders, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F] PBR06 is the first listed.
NCT01028209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01028209 about?
NCT01028209 is a clinical study titled "Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions". The underlying goal of this study is to assess \[18F\] PBR06 PET imaging as a tool to detect microglial activation in the brain of Alzheimer Disease (AD), Parkinson Disease (PD) and Multiple Sclerosis (MS) research participants.
What is the current status of trial NCT01028209?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2009-11. Estimated completion is 2010-09-22.
What interventions are being tested in trial NCT01028209?
The interventions under investigation include: [18F] PBR06 (DRUG).
Who is sponsoring clinical trial NCT01028209?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.